The estimated Net Worth of Niraj Vasisht is at least $1.52 Million dollars as of 24 March 2017. Niraj Vasisht owns over 530 units of Biodelivery Sciences International stock worth over $1,522,789 and over the last 9 years Niraj sold BDSI stock worth over $1,007.
Niraj has made over 6 trades of the Biodelivery Sciences International stock since 2016, according to the Form 4 filled with the SEC. Most recently Niraj sold 530 units of BDSI stock worth $1,007 on 24 March 2017.
The largest trade Niraj's ever made was exercising 141,647 units of Biodelivery Sciences International stock on 22 February 2017 worth over $791,807. On average, Niraj trades about 37,103 units every 46 days since 2016. As of 24 March 2017 Niraj still owns at least 272,413 units of Biodelivery Sciences International stock.
You can see the complete history of Niraj Vasisht stock trades at the bottom of the page.
Niraj's mailing address filed with the SEC is 4131 Parklake Ave #225, Raleigh, NC 27612, USA.
Over the last 21 years, insiders at Biodelivery Sciences International have traded over $111,671,776 worth of Biodelivery Sciences International stock and bought 1,813,177 units worth $5,352,510 . The most active insiders traders include International, L.P. Elliott, Associates, L.P. Elliott, and Healthcare Master Fund Ltd .... On average, Biodelivery Sciences International executives and independent directors trade stock every 18 days with the average trade being worth of $420,648. The most recent stock trade was executed by Jeffrey Allen Bailey on 9 March 2022, trading 5,333 units of BDSI stock currently worth $29,811.
BioDelivery Sciences International, Inc. is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.
Biodelivery Sciences International executives and other stock owners filed with the SEC include: